Application of Dehydrated Amniotic Membrane Allografts in Advanced Diabetic Foot Ulceration: Case Report and Review of Literature
Jul 20, 2022
by Catherine Becker 1,*, Matthew Regulski 2, Scott Martin 1 and Tyler Barrett 1
- Regenative Labs, 1700 Main Street, Pensacola, FL 32502, USA
- Ocean County Foot and Ankle Surgical Associates, 54 Bey Lea Road, Toms River, NJ 08753, USA
* Author to whom correspondence should be addressed.
Academic Editor: Nikolaos Papanas
Received: 30 June 2022 / Revised: 14 July 2022 / Accepted: 18 July 2022 / Published: 20 July 2022
The management of diabetic foot ulcers (DFUs) presents challenges to even the most experienced wound-care providers. Because of the chronic, non-healing nature of many DFUs, advances in the treatment and care of this disease process are particularly relevant. This case study aims to report the efficacy of the application of dehydrated amniotic membrane allograft (DAMA) to a diabetic foot ulcer. The patient in this study is a 44-year-old male who presented with an aggressive infection on his right foot, which resulted in an open wound of 18-month duration. This patient received weekly applications of dual-layer DAMA over seven weeks. Upon examination at the initial application, the wound was classified as a Wagner grade 3 with necrosis of the underlying muscle. Upon inspection at the final visit, the wound was closed entirely. The results that were shown include improvements in the size, depth, edges, necrotic tissue amount, and epithelization of the wound. This case study demonstrates that the application of DAMA has the potential to augment the body’s natural DFU healing response; however, future nonrandomized and randomized controlled trials are needed to establish its efficacy further.